LyncBio Therapeutics, an Emerging Innovator in ADC Development, Closes Pre-A Financing Round
Dec 25 , 2025
LyncBio Therapeutics (Shanghai) Co., Ltd. ("LyncBio"), a fast-growing biotech company in China dedicated to developing innovative Antibody-Drug Conjugates (ADCs) for both autoimmune disorders and cancer, recently announced the successful completion of the strategic Pre-A financing round.
The round was co-led by prominent investment firms Panlin Capital and Apricot Capital, with joint investments from Elikon Venture and Legend Star as follow-on investors. Proceeds from this financing round will be utilized to accelerate the clinical development of the company's lead candidate and strategically expand its rich therapeutic pipeline. This capital injection provides strong momentum for LyncBio's pursuit of its cutting-edge ADC technology and high-valued pipeline candidates
Previously, LyncBio Therapeutics completed tens of millions of RMB in seed round financing, with Apricot Capital — a venture capital firm focused on investments in the life sciences sector — acting as the lead investor.
Founded in September 2023, LyncBio leverages a proprietary, next-generation ADC technology platform. The company's lead pipeline candidate, a IBD targeting ADC therapeutics, has advanced rapidly. Within two years, the program completed in-house ADC design, GMP manufacturing, and GLP toxicology studies, and is in preparation for Investigational New Drug (IND) submission. The leading IBD asset holds significant potential to address a global unmet clinical need for over 15M IBD patients worldwide.
In the parallel tracks, LyncBio boasts multiple preclinical bispecific ADC assets at early-stage development, covering indications such as multiple sclerosis, solid tumors and multiple myeloma. This diversified portfolio reflects the company's strategic advantage: harnessing its Next Generation ADC Technology to enable synergistic, biology and disease-focused pipeline expansion.
Commenting on the financing, Dr. Cexiong Fu, Founder & CEO of LyncBio, stated:
“The successful closing of this round reflects strong investor confidence in our scientific innovation, robust R&D pipeline, and capable management team. At this pivotal juncture of our technological evolution, this capital infusion will significantly accelerate the clinical advancement of our lead program and the further development of our proprietary platform. This funding empowers us to expand into additional therapeutic areas with urgent unmet medical needs. Looking forward, LyncBio will focus on its core technology evolution, recruiting world-class elite talent, and expediting the launch of transformative medicines to offer new treatment options for patients worldwide.”
Mr. Yuhui Li, Founding and managing partner at one of the lead investors, Panlin Capital, added:
“LyncBio stands out with its highly differentiated competitive advantage across its pipeline and cutting-edge technology platform. The team has built deep technical expertise and demonstrated significant achievements in the ADC space. Their unique integration of global standards with local execution efficiency highlights the dynamism and strengths of this next-generation innovator. We have witnessed the company’s rapid growth and high operational excellence, which is truly exceptional in the highly competitive ADC landscape. We are excited to partner with LyncBio and continue to support the company in achieving sustained breakthroughs in innovative drug development.”
Dr. Qiang Jing, Managing Partner of Apricot Capital, remarked: "The rapid advancement in ADC technology is pioneering in paradigm-shifting evolution for both autoimmune and oncology therapeutics. LyncBio therapeutics taking a dual-engine pipeline strategy demonstrates strategic foresight in spearheading into multiple disease areas with unmet medical need and huge market potential."
"As the lead investor in the Seed and pre-A round, our conviction stemmed from LyncBio’s three-pronged advantages: vertically integrated ADC technology platform, critical ADC know-how and differentiated strategy, and keen insight on unmet clinical need. Their operational excellence has been evidenced by building zero-to-one development of lead assets from discovery to IND enabling within 24 months – an achievement that materially validates our initial technical due diligence and judgement."
"This follow-on investment embodies both recognition of their strong execution records and transformative potential of their next-wave ADCs. We anticipate this capital infusion will catalyze much-anticipated clinical validation of their flagship programs while enabling breakthrough into novel therapeutic opportunities, ultimately positioning LyncbBio therapeutics as a global competitor delivering impactful therapies that fuse cutting-edge innovation with tangible clinical value for patients worldwide. "
Following this financing, LyncBio will significantly increase its R&D investment to accelerate the clinical entry of its lead program while advancing the early-stage discovery efforts for multiple proprietary, novel ADC candidates. Regarding team building, the company will continue to attract global elite talent to optimize its talent ladder and rapidly grow its overall R&D innovation capabilities and operational efficiency. For external collaboration, LyncBio puts emphasis on engaging with Multinational Corporations (MNCs) and leading global investment firms to engage in potential investment and partnership opportunities.
About LyncBio Therapeutics
Co-founded in 2023 by Dr. Cexiong Fu and Dr. Jiajie Feng, LyncBio Therapeutics is an innovative drug development company pioneering a dual-focus strategy in Antibody-Drug Conjugate (ADC) research for both autoimmune disorders and oncology. The company is dedicated to the discovery and clinical translation of medicines that deliver durable patient value, relentlessly exploring the full potential of ADCs to address critical unmet clinical needs worldwide.